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SUMMARY
SNPs affecting disease risk often reside in non-coding genomic regions. Here we show that SNPs 
are highly enriched at mouse strain-selective adipose tissue binding sites for PPARγ, a nuclear 
receptor for antidiabetic drugs. Many such SNPs alter binding motifs for PPARγ or cooperating 
factors, and functionally regulate nearby genes whose expression is strain-selective and 
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imbalanced in heterozygous F1 mice. Moreover, genetically-determined binding of PPARγ 
accounts for mouse strain-specific transcriptional effects of TZD drugs, providing proof-of-
concept for personalized medicine related to nuclear receptor genomic occupancy. In human fat, 
motif-altering SNPs cause differential PPARγ binding, provide a molecular mechanism for some 
expression quantitative trait loci, and are risk factors for dysmetabolic traits in genome-wide 
association studies. One PPARγ motif-altering SNP is associated with HDL levels and other 
metabolic syndrome parameters. Thus, natural genetic variation in PPARγ genomic occupancy 
determines individual disease risk and drug response.
INTRODUCTION
A major unanswered question is how most genetic variation causes phenotypic differences, 
as only a small fraction of single nucleotide polymorphisms (SNPs) affect protein sequence 
(Shastry, 2002). Current genome-wide association studies (GWAS) reveal a large gap 
between known causal genes and the observed heritability of common diseases and 
treatment outcomes (Sadee et al., 2014). Another limitation of GWAS is that each locus 
nominates a large group of SNPs in linkage disequilibrium, such that causal and neutral 
variants cannot easily be distinguished. Non-coding SNPs in regulatory regions may affect 
transcription factor (TF) binding and gene expression, thus contributing to complex 
phenotypes like disease association and response to drugs (Edwards et al., 2013).
There are examples of regulatory variants causing Mendelian syndromes (De Gobbi et al., 
2006; Smemo et al., 2012), but such SNPs may be more likely to associate with complex 
non-Mendelian diseases in GWAS (Sakabe et al., 2012). Overall, putative causal GWAS 
SNPs cluster more in promoters and enhancers than in exons (Andersson et al., 2014), and a 
recent effort to computationally identify causal GWAS SNPs for autoimmune diseases 
found that ~90% were non-coding, with ~60% in distal immune cell enhancers (Farh et al., 
2015). A few specific examples have emerged. The causal SNP for an LDL cholesterol and 
myocardial infarction locus is a regulatory variant altering hepatic SORT1 expression 
(Musunuru et al., 2010). Regulatory SNPs in distant enhancers for MYC result in 
associations with multiple cancers (Sur et al., 2013), and an intronic enhancer SNP in 
TCF7L2 may mediate type 2 diabetes (T2D) risk (Gaulton et al., 2010). For the PPARG 
T2D locus, the causal SNP was thought to be a coding Pro12Ala polymorphism, yet recent 
evidence has implicated a tightly linked regulatory SNP (Claussnitzer et al., 2014).
PPARγ provides an excellent system to study effects of regulatory variation on TF binding, 
gene expression, drug response, and phenotype. PPARγ is a nuclear receptor TF required for 
adipocyte development (Wang et al., 2013) that activates many adipocyte genes. PPARγ is 
genetically implicated in metabolic disease, both through the common SNP associated with 
T2D (Altshuler et al., 2000), and also through rare ligand binding domain mutations causing 
an autosomal dominant syndrome of lipodystrophic insulin resistance (Barroso et al., 1999). 
Since variants affecting the PPARγ TF itself have these consequences, then genetic variation 
in key PPARγ genomic binding sites may similarly have metabolic effects.
PPARγ is also the target of antidiabetic thiazolidinedione (TZD) drugs, which have a unique 
and powerful insulin-sensitizing effect, yet clinical use has declined due to concerns over 
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side effects and adverse events (Soccio et al., 2014). Individuals differ in drug response, and 
~20–30% of diabetic patients fail to respond to TZDs (Sears et al., 2009). Most 
pharmacogenomic studies focus on coding or non-coding variants affecting the drug target 
itself, or drug-metabolizing enzymes and transporters (Mizzi et al., 2014). However, 
regulatory variants may potentially alter downstream transcriptional effects of drugs, either 
indirectly after signal transduction from a cell surface receptor, or directly in the case of 
DNA-binding nuclear receptors like PPARγ.
Here, we set out to determine whether non-coding regulatory variation could affect PPARγ 
genomic occupancy, and whether such SNP-dependent binding could affect gene 
expression, drug response, and metabolic phenotype. Chromatin immunoprecipitation 
followed by deep sequencing (ChIP-seq) was used to define genetically-determined 
variation in PPARγ sites genome-wide in white adipose tissue (WAT). In mice, sites with 
inbred strain-selective PPARγ genomic occupancy were highly enriched for SNPs, and in 
heterozygous F1 mice these SNPs had allelic imbalance in PPARγ binding. These SNPs 
often altered TF motifs, not only motifs for PPARγ but also motifs for other, cooperating 
TFs. Importantly, some strain-selective binding sites were functional regulating nearby gene 
expression in WAT, both basal and TZD-stimulated. Similar studies were performed in 
human WAT, where SNPs also led to imbalanced PPARγ binding. Remarkably, these 
human SNPs were enriched in WAT expression quantitative trait loci (eQTLs) as well as in 
regions linked to metabolic disease in GWAS. Thus, variable PPARγ occupancy due to 
SNPs determines nearby gene activation by PPARγ and its ligands, and these effects may 
underlie genetic differences in metabolic phenotypes and drug responses.
RESULTS
Genomic binding of PPARγ in mouse fat is strain-selective and driven by SNPs
ChIP-seq was performed in WAT from two inbred mouse strains, C57Bl/6J (B6) and 129S1/
SvImJ (129), which differ in susceptibility to obesity and insulin resistance (Almind and 
Kahn, 2004). Since highly polymorphic 129 sequencing reads may not align to the B6 
reference genome, the SNP-sensitive alignment tool GSNAP (Wu and Nacu, 2010) was used 
to eliminate alignment bias and identify truly strain-selective binding (Figures S1A–B). 
Three independent ChiP-seq experiments were performed (Table S1), allowing 
identification of strain-selective sites at high confidence (3-fold strain difference in reads at 
least 2 of 3 experiments) and highest confidence (all 3, Figure 1A). Average peak heights in 
F1 intercross progeny were intermediate between parents, while nonselective sites were 
equal in all three (Figure 1B), indicating that strain-selectivity of adipose genomic PPARγ 
occupancy was genetically determined. Of note, while WAT PPARγ cistromes include 
contributions of other cell types that express PPARγ, such as resident macrophages, the 
great majority of sites overlapped with those in 3T3-L1 adipocytes but not with previously 
reported macrophage-selective sites (Lefterova et al., 2010), thus likely represent adipocyte 
binding sites.
The B6 and 129 genomes differ by ~5.3 million SNPs (Keane et al., 2011), and strain-
selective sites were highly enriched for occurrence of SNPs (Figure 1C). Notably, SNPs 
falling in B6- or 129-selective sites showed PPARγ binding allelic imbalance in F1 WAT 
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favoring the allele with better parental binding, whereas SNPs in non-selective sites showed 
equal representation of both alleles (Figure 1D). F1 imbalance shows that cis-acting 
elements determine PPARγ occupancy, as selectivity is evident even when two alleles are in 
the same nucleus.
To further validate cis-acting PPARγ site SNPs, ChIP-seq was performed in 3T3-L1 
adipocytes, a cell line derived from outbred NIH Swiss albino mice (Todaro and Green, 
1963) and thus heterozygous at many loci. In these cells PPARγ bound at ~9,000 sites of 
B6:129 SNPs, and, importantly, at least 18% were heterozygous (Figure S1C). At 
heterozygous sites where PPARγ binding was strain-selective in B6 versus 129 WAT, the 
predicted allelic imbalance in binding was observed in 3T3-L1 adipocytes (Figure S1D). 
This is similar to F1 mice, and confirms the powerful effect of cis-acting SNPs on PPARγ 
genomic binding.
SNPs alter TF motifs to cause strain-selective PPARγ binding
PPARγ binds DNA at direct repeat 1 (DR1) motifs both in vitro (Tontonoz et al., 1994) and 
in 3T3-L1 adipocytes (Lefterova et al., 2008; Nielsen et al., 2008), and this was the top 
motif found in WAT PPARγ sites (Figure 2A). To test whether DR1-altering SNPs cause 
strain-selective binding, all polymorphic DR1 motifs in PPARγ binding regions were 
identified and assigned motif scores, such that the B6:129 score ratio indicated strain 
difference in consensus motif agreement. SNPs with large effects on PPARγ/DR1 motifs 
(ratio >16) were highly likely to show selective binding in the strain with the stronger motif, 
and unlikely to be selective for the opposite strain (Figure 2B). This discrimination was 
apparent even when SNPs had medium (8–16 fold) or small (2–8 fold) motif effects, but 
effectively lost when SNPs had minimal effects (<2-fold). While this analysis used 
thresholds for motif effects and binding difference, the same pattern emerged in a 
quantitative scatterplot analysis correlating binding ratio versus motif ratio (Figure S2A). 
This approach relies on natural B6:129 genetic variation at PPARγ motifs, but can be 
extended to other variants. For instance, 3T3-L1 PPARγ sites have 936 heterozygous SNPs 
that are non-polymorphic between B6 and 129, and when these SNPs altered PPARγ/DR1 
motifs, there was the predicted allelic imbalance in PPARγ occupancy (Figure S2B).
Individual nucleotide substitutions at each position of the DR1 motif (Figure S2C) were 
interrogated for PPARγ occupancy effects. Overall, this strongly validated the motif ratio 
approach, though there were informative exceptions where SNPs at some locations had large 
occupancy effects despite apparently small motif effects (Figure S2D–F). This reinforces a 
key point about consensus ChIP-seq motifs: they reflect nucleotide frequencies at motifs 
actually bound by the TF, but may not necessarily represent the strongest binding version of 
the motif. Also, in addition to the core DR1 motif, three upstream bases also determined 
PPARγ occupancy (Figure S2G), confirming in vivo the importance of 5’ flanking sequence 
as reported in prior in vitro studies (Juge-Aubry et al., 1997) and the X-ray crystal structure 
(Chandra et al., 2008). Finally, the most drastic effects on DR1 motifs and PPARγ binding 
occurred when multiple SNPs altered the same motif (Figure S2H).
PPARγ often binds DNA in close proximity to C/EBP TFs, and the two facilitate each 
other’s binding by assisted loading (Madsen et al., 2014). Consistent with other reported 
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PPARγ cistromes (Lefterova et al., 2008; Nielsen et al., 2008), at WAT PPARγ sites the top 
non-DR1 motif was for C/EBP (Figure 2A). As with DR1, SNPs with large C/EBP motif 
effects caused the predicted strain-selectivity in PPARγ occupancy (Figure 2C). In addition 
to PPARγ and C/EBP, a motif for the nuclear factor I (NFI) family was also enriched at 
PPARγ binding sites, consistent with previous reports (Rajakumari et al., 2013). SNPs with 
large NFI motif effects also gave strain-selectivity in PPARγ binding (Figure 2D), indicating 
that an NFI TF can modulate PPARγ genomic binding in vivo. Thus, in addition to the well-
known PPARγ-cooperating factor C/EBP, this SNP-based method can also suggest 
functional relevance for novel candidate TFs.
The next highest motif found in PPARγ sites was a glucocorticoid receptor (GR) motif, and 
SNPs altering this inverted repeat 3 (IR3) motif affected PPARγ occupancy (Figure 2E). The 
effect of IR3 motifs was independent, as an IR3 motif SNP never also affected an 
overlapping DR1. GR plays a major role in adipocyte biology (Steger et al., 2010). GR 
ChIP-seq performed in WAT from B6 and 129 mice revealed strain-selective GR binding 
(Figure S3A) at sites highly enriched for SNPs (Figure S3B), and SNPs in GR motifs had 
predicted effects on GR occupancy (Figure S3C). Moreover, the majority of PPARγ binding 
sites in WAT are also occupied by GR, and hundreds of sites had high confidence strain-
selective binding of both factors (Figure S3D). Many had motif-altering SNPs in PPARγ, 
GR, or C/EBP motifs, and all three types of SNPs could mediate strain-selective binding of 
both PPARγ and GR (Figure S3E–F). Therefore, SNPs altering PPARγ motifs not only 
affect PPARγ occupancy, but also binding of other TFs like GR. Conversely, PPARγ 
binding can be altered by SNPs in PPARγ motifs as well as motifs for other TFs, showing 
the powerful effect of motif SNPs on cooperative binding of multiple TFs.
Selective sites with SNPs but not identifiable motifs (Figure S3G) may be due to SNPs 
affecting degenerate or non-consensus motifs for these TFs or other TF motifs, yet many 
strain-selective sites are non-polymorphic over 200bp. Such unexplained strain-selective 
sites, with or without SNPs, may result from long-range interactions with other sites in the 
same locus, and this is consistent with the observed clustering of both B6 and 129-selective 
binding sites near other sites selective for the same strain (Figure S3H).
Strain-selective PPARγ binding functions to modulate nearby gene expression
The great majority of PPARγ sites, including the genetically determined sites defined here, 
reside outside promoters >5kb from transcription start sites (TSSs). The function of sites as 
enhancers correlates with occupancy of cofactors such as Med1 and p300, as well as with 
transcription of enhancer RNA (eRNA) identified by global run-on sequencing (GRO-seq) 
(Hah et al., 2013; Step et al., 2014). GRO-seq was performed in WAT from B6 mice, and 
eRNA was quantified at PPARγ sites. High eRNA transcription in B6 WAT was present at 
~18% of B6-selective sites, a significant three-fold enrichment versus the 129-selective sites 
with little PPARγ binding in B6 mice, the majority of which had no detectable eRNA 
transcription (Figure 3A). Thus, strain-selective PPARγ binding in WAT correlated with 
functional enhancer activity defined by eRNA transcription. Moreover, ChIP-seq for 
coactivators in 3T3-L1 adipocytes (Step et al., 2014) revealed imbalanced occupancy of 
p300 (Figure 3B) and Med1 (Figure S4A) at heterozygous sites with the same imbalance in 
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PPARγ binding. Thus, allele-selective PPARγ occupancy robustly predicts cofactor 
occupancy and differential enhancer function.
To test for function of strain-selective PPARγ sites in gene regulation, RNA-seq was 
performed in four separate experiments using WAT from B6 and 129 mice (Table S2), 
revealing 432 genes with consistently higher expression in one strain (Figure 3C). RNA-seq 
was also performed in WAT from F1 mice, and genes with strain-differential expression 
showed the predicted imbalanced expression in F1s, indicating cis effects (Figure S4B). 
Strain differences in gene expression observed in WAT were also found in primary 
adipocytes differentiated in cell culture (Figure S4C), further supporting genetic 
determination.
To integrate strain-differential gene expression with PPARγ binding, we identified the 
nearest strain-selective site within 50kb in either direction from each TSS. For genes with 
B6-higher expression, the nearest selective PPARγ site was B6-selective 4 times as often as 
129-selective (Figure 3D). Conversely, a 5-fold enrichment for 129-selectivity of the nearest 
PPARγ site was observed for genes whose expression was higher in 129 WAT. By contrast, 
strain-similar genes were equally unlikely to be near to B6- or 129-selective sites. There was 
also a marked effect of distance, such that if a strain-differential gene TSS was within 5kb of 
the strain-selective site, gene expression and PPARγ binding nearly always favored that 
same strain (Figure S4D). If the nearest strain-selective site was 5 to 50kb away, there was 
~2-fold same-strain preference for gene expression, but this was lost for distances 50 to 
100kb. The consistent direction of effects and their proximity dependence strongly suggest 
that PPARγ binding is causing differential gene expression. For example, Sgcg expression is 
much higher in 129 WAT, and in its first intron ~600bp from the TSS lies a 129-selective 
PPARγ site (Figure 3E) with a 129-stronger DR1 motif SNP (Figure 3F). In F1 WAT, 
expression is intermediate, with PPARγ binding and gene expression both demonstrating 
allelic imbalance highly favoring 129 alleles. Although no characteristic of strain-selective 
PPARγ binding was fully predictive of differential gene expression, sites with strain-
selectivity in both binding and nearest gene expression were on average stronger (Figure 
S4E), nearer to the gene’s TSS (Figure S4F), associated with fewer nearby and potentially 
redundant sites (Figure S4G), and enriched for a helix-loop-helix TF-binding motif (Figure 
S4H) compared to control sites (non-selective or strain-selective without differential nearest 
gene expression).
Functional PPARγ site SNPs have potentially powerful applications to genetic studies. B6 
and 129 mice differ in their susceptibility to obesity, and several quantitative trait loci 
(QTLs) for this phenotype have been mapped (Lin et al., 2013). One effort used 
computational tools to narrow QTL intervals (Su et al., 2008), and within these we find 5 
cases of strain-selective WAT gene expression attributable to PPARγ binding (Figure S5A). 
For instance, the Zdhhc2 gene encodes a palmitoyltransferase and a 129-selective PPARγ 
site is in nearby gene intron, with a DR1 motif-altering SNP favoring 129 (Figure S5B–C). 
Zdhhc2 expression is 129-higher, and there is also the predicted F1 imbalance in expression 
and PPARγ binding. The PPARγ site was validated by ChIP and quantitative PCR showing 
high binding in 129, absent binding in B6, and intermediate binding in F1 WAT (Figure 
S5D). Furthermore, an allelic imbalance assay on the F1 ChIP PCR product confirmed the 
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imbalance observed by ChIP-seq (Figure S5E). Thus, genetically-determined adipose 
PPARγ binding that affects gene expression nominates mechanistic candidates for several 
mouse obesity QTLs.
Strain-selective PPARγ binding mediates differential responses to antidiabetic drugs
Rosiglitazone (rosi) is an antidiabetic TZD drug that functions as a high-affinity activating 
ligand for PPARγ (Lehmann et al., 1995). To determine whether genetic differences in 
PPARγ binding affect TZD response, B6 and 129 mice were treated with rosi for 2 weeks, 
then RNA-seq of WAT was performed (Table S2). Rosi up-regulated (Figure 4A) and 
down-regulated (Figure S6A) genes were classified by statistical significance in both strains 
versus B6-only or 129-only. Integration of these genes with nearby strain-selective PPARγ 
binding revealed that genes rosi-up only in B6 mice were much more likely be near a B6-
selective sites, and genes that were rosi-up only in 129 mice likewise showed more nearby 
129-selective sites (Figure 4B). By contrast, there was no such discrimination in four control 
gene classes: those rosi-up in both strains were equally likely to be near B6- and 129-
selective sites (Figure 4B), as were all groups of rosi-down genes (Figure S6B). This latter 
result is remarkably consistent with the recent finding that adipocyte gene repression by rosi 
is unrelated to nearby PPARγ binding (Step et al., 2014). As an example, the Abhd3 gene, 
encoding a phospholipid lipase (Long et al., 2011), was rosi-up by 2-fold only in 129 mice 
(Figure 4C), consistent with an upstream 129-selective PPARγ site (Figure 4D) with a 129-
stronger DR1 motif-altering SNP (Figure 4E). Other examples of strain-selective rosi-
induced genes are shown in Figure S6C. Allele-dependent response to rosi was also 
measured in 3T3-L1 adipocytes by analyzing GRO-seq data (Step et al., 2014) for allelic 
imbalance in gene body transcription. The rosiglitazone-induced gene Dhrs9 has two 
haplotypes (reference and other) in 3T3-L1 cells, with 50 heterozygous SNPs in the gene 
(Figure 4F). In the absence of rosi, these SNPs showed imbalanced transcription favoring 
reference alleles (Figure 4G). Rosi elicited a selective increase in transcription of reference 
but not other alleles, and thus significantly increased the imbalance (Figure 4G–H). This 
haplotype-selective effect of rosi on Dhrs9 transcription correlated with PPARγ occupancy, 
as two sites near the TSS harbor SNPs with imbalanced PPARγ binding strongly favoring 
reference alleles (Figure 4F). These data demonstrate the pharmacogenomic role of 
regulatory SNPs in determining transcriptional response to a drug, in this case by altering 
PPARγ genomic binding.
Motif-altering SNPs determine PPARγ occupancy and gene expression in human fat
Humans are outbred and any two unrelated individuals differ at SNPs in ~0.1% of the 
genome (Shastry, 2002), similar to the difference between B6 and 129 mice. The above 
mouse findings are not directly applicable to humans, since the great majority of adipocyte 
PPARγ sites are not retained at syntenic genomic positions between the species (Mikkelsen 
et al., 2010; Soccio et al., 2011), and entirely different SNPs exist as they arose after 
speciation. Therefore, to determine the effects of SNPs on PPARγ genomic occupancy, 
ChIP-seq was performed on human subcutaneous adipose tissue from five individuals (Table 
S3). SNPs were identified based on three criteria: (1) annotated in dbSNP141 with minor 
allele frequency >1%, (2) located in a PPARγ binding site identified by ChIP-seq in one or 
more subjects, and (3) altered an identifiable PPARγ or C/EBP motif. To test for effects of 
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motif alterations, a subset of SNPs was identified as heterozygous in at least one subject as 
defined by detection of both alleles in ChIP-seq reads; imbalanced PPARγ binding in 
heterozygous subjects was investigated by the same method used in F1 mice and 3T3-L1 
cells. Remarkably, and similar to mouse, human SNPs altering motifs for PPARγ (Figure 
5A) or C/EBP (Figure 5B) led to imbalanced binding in heterozygotes favoring the alleles 
with stronger motifs. Thus, motif-altering SNPs determine PPARγ binding in human fat. 
Indeed, this effect was sizable even though heterozygous cases with 100% imbalance, which 
appear homozygous in the ChiP-seq data, could not be identified by this analysis.
To test for function regulating nearby human genes, all candidate PPARγ site motif-altering 
SNPs (regardless of heterozygosity) were integrated with human eQTLs identified in fat 
biopsies from 1,381 Finnish men in the METSIM cohort (Stancáková et al., 2012). These 
subjects had genotyping and adipose gene expression analyses, and cis eQTLs fell within 1 
Mb of a gene and were significantly associated with its expression level (see Extended 
Procedures). Within each eQTL, the expression SNP (eSNP) was defined as most 
significantly associated and thus most likely to be causal. There was a significant 3-fold 
enrichment of eSNPs in strong candidate motif-altered SNPs relative to an internal control 
set of PPARγ site SNPs with only minimal motif effects (Figure 5C). SNPs with small or 
medium motif effects showed intermediate 2.3-fold enrichment, while the strongest 
candidate PPARγ site SNPs (those from Figure 5A–B showing imbalance in heterozygous 
subjects favoring the stronger motif) were dramatically and significantly enriched 7-fold for 
eSNPs (Figure 5C).
The direction of each eQTL was tested to determine whether the stronger motif allele was 
associated with higher gene expression. For all SNPs in the eQTL dataset, there was an even 
distribution with 50.09% of reference alleles positively associated with expression. Analysis 
PPARγ and C/EBP motif-altering eSNPs revealed 70–80% positive eQTL association for 
those strongest candidate SNPs with observed imbalance in heterozygotes (Figure 5D). By 
contrast, control eSNPs with minimal motif effects showed the ~50% positive association 
expected by chance, while greater motif changes led to more positive association with gene 
expression, strongly indicating causality (Figure 5D). Based on interrogation of this large 
and powerful eQTL dataset, motif-altering SNPs affecting PPARγ occupancy are functional 
in determining the expression of nearby genes in human fat.
For example, rs568867 is a highly significant eSNP for TMEM170B gene expression (odds 
ratio 2.25, P=3.3e-86), and higher expression with the G allele was confirmed in fat biopsies 
from 23 human subjects (Figure 6A). TMEM170B encodes an uncharacterized 
transmembrane protein, and its mRNA is strongly induced during mouse and human 
adipocyte differentiation (Figure 6B) consistent with PPARγ gene regulation. The SNP falls 
in a PPARγ site 12kb upstream, in a DR1 with the G allele giving a stronger motif (Figure 
6C), and ChIP from a heterozygous subject confirmed selective PPARγ binding to the G 
allele (Figure 6D). Furthermore, an exonic SNP in the TMEM170B 3’ UTR allowed 
measurement of allelic imbalance in mRNA expression. 11 subjects were heterozygous for 
this mRNA SNP, and imbalanced TMEM170B expression was only observed in those 3 
subjects G/A heterozygous at the PPARγ binding site SNP (Figure 6E). This correlation is 
highly suggestive that imbalanced PPARγ binding upstream of TMEM170B causes 
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imbalanced gene expression, and other human regulatory SNPs likewise affect PPARγ 
binding and function.
SNP-dependent PPARγ binding underlies human metabolic phenotypic differences
Human PPARγ site motif-altering SNPs were interrogated in published GWAS meta-
analyses for 8 metabolic traits (see Extended Procedures). SNPs that altered PPARγ or 
C/EBP motifs in PPARγ sites were highly enriched among SNPs associated with 
triglyceride (TG) and HDL cholesterol (HDL) levels (Figure 7A). For TG, the odds ratio 
was 1.84 (95% confidence interval of 1.27–2.66), and for HDL the odds ratio was 1.76 
(1.22–2.56). In both cases, this nearly 2-fold enrichment was beyond that expected by 
chance, even accounting for multiple testing.
Since PPARγ site motif-altering SNPs are enriched for dyslipidemia trait associations, some 
may be mechanistically implicated. We focused on an HDL-associated PPARγ motif-
altering C:T SNP (rs392794), for which the T allele favors PPARγ binding (Figure 7B). 
There was significantly higher PPARγ-dependent activation of a reporter with a T allele (31-
fold) versus the C-allele (7-fold, Figure 7C). The T allele that gives higher PPARγ 
transcriptional activity is associated with lower HDL, and this association reached genome-
wide significance at P=8.1e-09 (below the standard threshold of P=5e-08). This novel 
association is independent of a reported dyslipidemia locus ~55kb away marked by another 
SNP (Global Lipids Genetics Consortium et al., 2013) which is not tightly linked (Figure 
7D, red arrow indicates a recombination hotspot between the SNPs). Furthermore, 
conditional analysis to remove the effects of the previously reported SNP showed that the 
PPARγ motif-altering SNP maintained a strong independent association with HDL 
(P=3.3e-06). In addition to HDL, this PPARγ motif-altering SNP rs392794 was also found 
to be associated with other metabolic traits, including serum TG, waist-hip ratio, and 
systolic blood pressure (Figure 7E). Thus, PPARγ occupancy and transcriptional activity at 
this site in human WAT may provide the mechanism for association with multiple traits that 
are part of the metabolic syndrome (Grundy et al., 2004).
DISCUSSION
Non-coding regulatory variants are key to understanding differences among individuals. 
Here we show that SNPs affect TF genomic occupancy, gene expression, and drug response 
in adipose tissue. Moreover, PPARγ site SNPs in human fat may modulate genetic risk of 
metabolic disease.
Previous studies have shown that TF binding among mammalian species differs in numerous 
cases even when the motif is intact (Mikkelsen et al., 2010; Schmidt et al., 2010; Soccio et 
al., 2011), and many are accounted for by variants affecting co-bound TFs (Schmidt et al., 
2011; Stefflova et al., 2013). Here we show this applies within a species, as SNPs affect 
PPARγ occupancy in WAT by altering motifs for PPARγ itself or other cooperating TFs. A 
similar phenomenon was reported in macrophages from inbred mouse strains, where SNPs 
altering PU.1 motifs and binding also affected binding of C/EBPα, and vice versa (Heinz et 
al., 2013). The mechanism likely involves cooperativity by assisted loading, which has been 
shown for recombinant PPARγ and C/EBPα in immortalized cell lines (Madsen et al., 
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2014). The present study demonstrates that these principles apply in living tissues in mice 
and man.
Motif-altering SNPs accounted for ~20% of strain-selective PPARγ binding between two 
mouse strains, even when only the top four TF motifs in PPARγ binding regions were 
considered. The majority of SNPs in strain-selective sites failed to alter recognizable motifs, 
consistent with a recent report that GWAS causal variant SNPs are highly enriched in tissue-
specific enhancers, yet only 10–20% directly alter motifs while most are “motif adjacent” 
(Farh et al., 2015). There was also clear strain-selective binding at non-polymorphic PPARγ 
sites, and we provide evidence for a novel mechanism based on the observed clustering of 
strain-selective sites: a causal polymorphic site may drive differential binding at other sites 
by long range interactions within a regulatory locus. Conversely, we observed numerous 
cases of motif-altering SNPs that failed to give strain-selective PPARγ binding, consistent 
with prior reports and presumably attributable to factors such as specific motif alterations, 
distance to peak center, presence of alternative motifs, and “buffering” by site context 
(Heinz et al., 2013; Maurano et al., 2012).
We found many examples in which genes nearest to mouse strain-selective PPARγ sites 
showed differential expression, and this enrichment was evident genome-wide for basal or 
rosiglitazone-induced adipose gene expression. The consistent direction of PPARγ 
occupancy and gene regulation effects (i.e. B6-stronger motif SNPs with B6-selective 
binding and B6-higher gene expression) argues strongly for causality. Similarly in humans, 
motif-altering PPARγ site SNPs showed enrichment for eQTLs in the predicted direction. 
Our approach used SNPs as “experiments of nature” to identify candidate functional binding 
sites among the multitude of sites that surround some genes, but further experiments will be 
necessary to elucidate the mechanisms underlying “functional” versus “non-functional” 
binding events, which is a major unanswered question in the field and may involve enhancer 
activity and/or 3D-looping events. Indeed, the majority of strain-selective sites did not have 
a detectable effect on the nearest expressed gene (though the actual targets may be more 
distant). Apparently non-functional regulatory variation may result from multiplicity and 
redundancy of enhancers around target genes (Cusanovich et al., 2014), as adipocyte gene 
expression has been correlated with the number of nearby PPARγ sites (Step et al., 2014). 
Just as PPARγ regulatory variation is not always functional, only a subset of differential 
genes are explained by PPARγ regulatory variation, as myriad other factors could affect 
adipose gene expression or response to TZD – yet our genome-wide methods had the power 
to identify the important cases of functional regulatory variation.
In addition to regulating basal adipose tissue gene expression, genetic variation at PPARγ 
sites also determines response to PPARγ ligand rosiglitazone. While there were more strain-
selective TZD-induced genes than could be accounted for by PPARγ sites, and thus other 
strain effects drive some of the observed variability in drug response, genetically determined 
differential PPARγ binding emerged as a clear mechanism for some strain-selective 
rosiglitazone effects. This provides proof-of-concept that naturally occurring genetic 
variation can affect nuclear receptor ligand-mediated gene activation and, more generally, 
drug response in living animals. This has special significance for TZDs, which have 
powerful antidiabetic effects but limited clinical utility due to adverse effects including bone 
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loss and edema (Soccio et al., 2014). The target genes responsible for TZD efficacy and side 
effects are unknown, but genetically-determined differences in TZD activation of such genes 
may underlie inter-individual differences in drug response. PPARγ cistromes are cell-type 
specific (Lefterova et al., 2010), and thus a given SNP might differentially impact the 
therapeutic and harmful effects of TZDs, particularly since many TZD side effects likely 
reflect non-adipose tissues. Understanding regulatory variation could lead to personalized 
PPARγ agonist therapy based upon individual profiles of SNPs that alter PPARγ binding.
There is great potential linking regulatory variation to human genetics of disease 
susceptibility revealed by GWAS. A recent effort to identify causal GWAS SNPs and their 
tissue effects showed that SNPs affecting TG and HDL fell in enhancers from adipose tissue 
(Farh et al., 2015). The present work shines a bright light on the role of PPARγ in this 
context, as the polymorphic PPARγ sites that we identified in human fat were enriched for 
the same dyslipidemic GWAS traits.
Detailed study of one PPARγ motif-altering SNP, rs392794, revealed its association with 
several metabolic syndrome traits. Of note, in GWAS meta-analyses a near-perfect proxy 
(rs459193) has been identified as the lead SNP in finely-mapped loci for both T2D (Morris 
et al., 2012) and waist-hip ratio (Shungin et al., 2015). Thus, the PPARγ site SNP identified 
here could be responsible for these associations with T2D and visceral adiposity, as well as 
the other metabolic traits reported here. While the GWAS locus is named for ANKRD55, 
this gene is quite distant (TSS 279kb away) and not expressed in adipose tissue, and we 
were unable to link the metabolism-associated PPARγ site to ANKRD55 or any other gene. 
Thus the target gene for this PPARγ-bound enhancer and the GWAS effect is unknown, and 
further studies will be necessary to understand how differential SNP-dependent PPARγ 
occupancy at this site may alter systemic metabolic phenotypes.
In sum, SNPs affect adipose PPARγ genomic occupancy and the basal and drug-induced 
expression of nearby genes. SNPs that alter PPARγ binding are enriched in loci affecting 
metabolic traits, such that they contribute to an individual’s metabolic disease risk. They 
also impact personalized pharmacogenomics, as better understanding of the tissue-specific 
functions of such SNPs has the potential to improve the risk/benefit ratio for TZD therapy in 
individual patients based on their genomes. The implications of this work go beyond PPARγ 
to all drug targets that function directly at the genome to regulate physiology in health and 
disease.
EXPERIMENTAL PROCEDURES
Mouse and human adipose tissue samples
Male wild type inbred C57Bl/6J and 129S1/SvImJ mice, in addition to the F1 intercross 
progeny (B6129SF1/J), were purchased from Jackson Laboratories, and all care and use 
procedures were approved by the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. Human fat samples (Table S3) were obtained from the Human 
Adipose Resource (HAR) of the Penn Institute for Diabetes, Obesity, and Metabolism, 
which obtains pre-operative informed consent from surgical patients for biopsies to be taken, 
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banked, and distributed to investigators with de-identified patient characteristics. All HAR 
protocols were approved by the University of Pennsylvania’s Institutional Review Board.
ChIP-seq, RNA-seq, and GRO-seq
Three related experiments compared PPARγ ChIP-seq in WAT from male mice of the B6 
and 129 strains, with minor differences in age, depot (epididymal versus inguinal), and diet 
(chow versus low fat control diet, Table S1). The great concordance among the three 
experiments allowed high confidence identification of genetic effects. The ~5.3 million 
known SNPs differing between B6 and 129 mice (Keane et al., 2011) were incorporated into 
SNP-sensitive GSNAP read alignments (Wu and Nacu, 2010). The HOMER software suite 
(Heinz et al., 2010) was used for peak identification and quantification. Motif identification 
and determination of SNP effects on motifs was performed as described in the Extended 
Procedures. Four related experiments compared WAT RNA-seq from male mice of the B6 
and 129 strains, with one also measuring the effect of rosiglitazone treatment for 2 weeks 
(Table S2). GRO-seq was performed, and eRNAs were identified and quantitated as 
previously described (Fang et al., 2014), with minor modifications for mouse WAT samples. 
All deep sequencing (single end 50 or 100bp reads) was performed by the Functional 
Genomics Core of the Penn Diabetes Research Center using Illumina HiSeq2000 and the 
Solexa Analysis Pipeline. Allelic imbalance was assayed in aligned sequence read BAM 
files using an allele counting PERL script.
Other methods
Quantitative PCR was performed using ABI 7500 Fast Real-Time PCR System and Power 
SYBR Green PCR Master Mix (Applied Biosystems). Allelic imbalance was confirmed at 
individual loci using the SNaPshot assay (Applied Biosystems). See Extended Procedures.
Statistical methods
Prism (Graphpad) was used for graphing and statistical tests, all of which are described in 
figure legends.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. SNPs genetically determine mouse strain-selective PPARγ sites
(A) ChIP-seq in mouse WAT identified ~35,000 PPARγ sites, and the heat map shows 2,226 
B6 or 129 strain-selective sites in 3 independent experiments. High confidence sites were 3-
fold strain-selective in 2, while highest confidence were in all 3. (B) For the five PPARγ site 
classes, average binding profiles are shown for the two inbred strains (B6 red, 129 blue) and 
F1 progeny (green). (C) For the five classes, occurrence of one or more B6:129 SNPs in 
each site’s central 200bp is shown, with enrichment of SNPs in strain-selective sites 
(*P<0.0001 versus non-selective sites by Chi-squared test). (D) In F1 ChIP-seq, allelic 
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imbalance was assayed in binding sites with SNPs (*P<0.0001 versus non-selective sites by 
Mann-Whitney test, 2-tailed). See also Figure S1, Table S1.
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Figure 2. PPARγ binding is altered by SNPs affecting motifs for PPARγ or other TFs
(A) Consensus motif logos for the four top scoring motif families found in PPARγ binding 
regions, with Cistrome identifiers and Z-scores. (B) Strain-selectivity of PPARγ binding 
sites at motif-altering SNPs divided into 4 classes based on size of the allelic effect on 
consensus motif agreement. (C–E) The same analysis for C/EBP, NFI, or GR motif-altering 
SNPs. The difference between SNPs with large and minimal motif effects was P<0.0001 in 
B and C, P=0.0026 in D, P=0.039 in E (Chi-squared test). See also Figure S2–S3, Table S1.
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Figure 3. Mouse strain-selective PPARγ sites drive differential WAT gene expression
(A) eRNA transcription in B6 WAT was measured by GRO-seq. By Chi-squared test, 
P<0.0001 for eRNA distribution, enriched in B6-selective sites. (B) 373 SNPs in mouse 
3T3-L1 adipocytes had adequate read depth (10+) in both PPARγ and p300 ChIP-seq, and 
allelic imbalance in p300 occupancy correlated with imbalance in PPARγ occupancy (linear 
regression r2=0.4 and P<0.0001 for a non-zero slope). Inset shows that, at 2-fold threshold, 
~60% of SNPs with imbalanced PPARγ binding had p300 imbalance in the same direction, 
while only ~3% had p300 imbalance in the opposite direction. (C) Four RNA-seq 
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experiments identified ~13,000 genes expressed in WAT, and 432 genes showed significant 
strain-differential expression >1.5-fold in at least 3 experiments. (D) For the three gene 
classes, the nearest strain-selective binding site within 50kb of the TSS was identified, 
demonstrating that strain-differential genes enrich for sites selective for the same strain. By 
Chi-squared test, P<0.0001 for strain-similar versus B6- or 129-higher, and for B6- versus 
129-higher. (E) Representative RNA-seq and ChIP-seq browser tracks are shown at the Sgcg 
gene, with 129-higher expression and a 129-selective PPARγ site (yellow). (F) The 
consensus PPARγ/DR1 motif logo is shown, above the motif sequences in both strains at the 
Sgcg binding site, with SNP alleles colored and showing their difference in motif agreement. 
See also Figure S4–S5, Table S2.
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Figure 4. Mouse strain-selective PPARγ sites drive differential gene activation by rosiglitazone
(A) RNA-seq identified rosi-regulated genes in WAT, and the heat map shows those with 
statistically significant increases in both strains (both EDGE M P<0.001) versus only one 
(P<0.001 but P>0.01 in the other strain). (B) For the three classes of genes, the nearest 
strain-selective binding site within 50kb of the TSS was identified. By Chi-squared test, 
P<0.01 for B6-only versus 129-only, and P<0.05 for the overall distribution. (C) The gene 
Abhd3 was rosi-up only in 129 WAT. A 129-selective PPARγ site (yellow) is upstream of 
the Abhd3 TSS (D), with a motif-altering SNP favoring the 129 allele (E). (F) In 3T3-L1 
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adipocytes, PPARγ ChIP-seq showed two sites near the Dhrs9 TSS (*), each with a 
heterozygous central SNP imbalanced favoring the reference allele by 3–4 fold. GRO-seq 
showed a significant 40% rosi-induction of positive strand transcription of Dhrs9, with 50 
heterozygous SNPs in the gene body. (G) Counting reference and other alleles at these SNPs 
showed baseline imbalance favoring reference alleles, and that rosiglitazone selectively 
activated only the reference haplotype. (H) At these SNPs, rosi significantly increased the 
average amount of imbalance. In C and H, mean and SEM, with ***P<0.0001, **P<0.01, 
*P<0.05, NS=not significant, by unpaired T-test, 2-tailed). See also Figure S6, Table S2.
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Figure 5. Human motif-altering SNPs affect PPARγ occupancy and nearby gene expression
Human PPARγ sites were found by ChIP-seq in WAT from 5 subjects, and SNPs in these 
sites were identified that altered PPARγ/DR1 or C/EBP motifs. (A) PPARγ-motif altering 
SNPs heterozygous in one or more subjects were assessed for 2-fold allelic imbalance in 
ChIP-seq reads, demonstrating that SNPs with larger motif effects showed enrichment for 
higher PPARγ binding to the stronger motif allele. (B) The same analysis for C/EBP motif-
altering SNPs, which also affected PPARγ binding. By Chi-squared test, the difference 
between SNPs with large and minimal motif effects was P=0.0002 in A and P=0.002 in B. 
(C) Motif-altering SNPs were interrogated for effects on nearby gene expression in human 
WAT eQTLs, and the best candidates with large motif effects or imbalance in heterozygotes 
(as in A-B) showed significant enrichment for eSNPs. (D) For PPARγ or C/EBP motif-
altering SNPs with eQTLs, the direction of association was tested, and for the best 
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candidates the stronger motif alleles were associated with higher gene expression. In C and 
D, **P<0.01, *P<0.05 by Fisher’s Exact Test, one-tailed. See also Table S3.
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Figure 6. Human TMEM170B gene expression driven by a polymorphic PPARγ site
(A) In 23 subjects, the G:A eQTL SNP rs568867 was genotyped and WAT TMEM170B 
gene expression was measured by Q-RT-PCR, validating genotype effects on expression 
(*P<0.05 versus G/A by Mann-Whitney test). (B) Murine 3T3-L1 or human SGBS cultured 
cells were differentiated to adipocytes and treated with rosiglitazone, with effects on 
TMEM170B gene expression. (C) Location of rs568867 PPARγ motif-altering SNP and a 
weakly linked (r2=0.513) SNP rs295051 in the mRNA 3’ UTR. (D) ChIP allelic imbalance 
assay in a G/A heterozygous subject. (E) Allelic imbalance in TMEM170B mRNA was 
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dependent on the rs568867 PPARγ site genotype. In B, D, and E, ***P<0.0001, **P<0.01, 
*P<0.05 by T-test, 2-tailed, unpaired.
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Figure 7. PPARγ site motif altering SNPs affect human metabolic GWAS traits
(A) Candidate human SNPs in PPARγ sites with more than minimal effects on PPARγ or 
C/EBP motifs were interrogated for enrichment in loci with a threshold P<0.01 for 8 GWAS 
traits: lipid levels (TG, HDL, LDL), body mass index (BMI), waist hip ratio corrected for 
BMI (WHR), T2D, coronary heart disease (CHD), and systolic blood pressure (SBP). (*Chi-
squared P<0.00625, significance threshold with Bonferroni correction for multiple testing of 
8 traits). (B) One HDL-associated PPARγ motif-altering SNP (rs392794) fell ~300kb from 
the ANKRD55 gene, with the T allele giving a stronger motif. (C) Luciferase reporters with 
the T and C alleles at this SNP were transiently transfected into 293T cells with or without 
expression plasmids for PPARγ and RXRα, and the T allele reporter gave higher PPARγ-
dependent activity (*P<0.01 by unpaired T-test, two-tailed). (D) Locus zoom plot showing 
this SNP has a genome-wide significant association with HDL, and it was not linked to the 
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nearby previously-described lipid association at SNP rs9686661, with a low r2 value and a 
recombination hot spot (red arrow) between the SNPs. (E) In addition to the HDL 
association (orange), this SNP had significant associations with other metabolic traits 
(P<0.005 in green). For D and E, associations for rs392794 are via the near perfect proxy 
rs459193 (r2=0.957) which was genotyped in the GWAS.
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